TY - JOUR
T1 - Expansion of chemical space based on a pyrrolo[1,2-a]pyrazine core
T2 - Synthesis and its anticancer activity in prostate cancer and breast cancer cells
AU - Seo, Yohan
AU - Lee, Jeong Hwa
AU - Park, So hyeon
AU - Namkung, Wan
AU - Kim, Ikyon
N1 - Publisher Copyright:
© 2019 Elsevier Masson SAS
PY - 2020/2/15
Y1 - 2020/2/15
N2 - In connection with our continued research to generate new aza-fused heteroaromatic chemical scaffolds, we developed a highly atom-economical three-component route to novel 3,4-dihydropyrrolo[1,2-a]pyrazine ring skeleton multi-functionalized on the pyrazine unit. This [4+1+1] annulation approach led us to gain access to a new N-fused bicyclic chemical space having two distinctive functional groups (heteroaryl and aroyl) in a trans manner. Investigation of anticancer activity of the synthesized compounds and their derivatives revealed that (3R*,4S*)-3-(4-bromophenyl)-4-(4-fluorobenzoyl)-2-(2-oxo-2-phenylethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2-ium bromide (3h) has potent anticancer activity. 3h significantly inhibited cell viability in prostate cancer cells (PC-3) and breast cancer cells (MCF-7) with IC50 value of 1.18 ± 0.05 μM and 1.95 ± 0.04 μM, respectively. In addition, 3h strongly reduced cell migration in a dose dependent manner, and induced apoptosis via caspase-3 activation and cleavage of PARP in PC-3 and MCF-7 cells. Our results in this study imply that 3h can be a potential anticancer agent against prostate cancer and breast cancer.
AB - In connection with our continued research to generate new aza-fused heteroaromatic chemical scaffolds, we developed a highly atom-economical three-component route to novel 3,4-dihydropyrrolo[1,2-a]pyrazine ring skeleton multi-functionalized on the pyrazine unit. This [4+1+1] annulation approach led us to gain access to a new N-fused bicyclic chemical space having two distinctive functional groups (heteroaryl and aroyl) in a trans manner. Investigation of anticancer activity of the synthesized compounds and their derivatives revealed that (3R*,4S*)-3-(4-bromophenyl)-4-(4-fluorobenzoyl)-2-(2-oxo-2-phenylethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2-ium bromide (3h) has potent anticancer activity. 3h significantly inhibited cell viability in prostate cancer cells (PC-3) and breast cancer cells (MCF-7) with IC50 value of 1.18 ± 0.05 μM and 1.95 ± 0.04 μM, respectively. In addition, 3h strongly reduced cell migration in a dose dependent manner, and induced apoptosis via caspase-3 activation and cleavage of PARP in PC-3 and MCF-7 cells. Our results in this study imply that 3h can be a potential anticancer agent against prostate cancer and breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85077233871&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077233871&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2019.111988
DO - 10.1016/j.ejmech.2019.111988
M3 - Article
C2 - 31901746
AN - SCOPUS:85077233871
SN - 0223-5234
VL - 188
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
M1 - 111988
ER -